COVID 19 anti CD40 CoV2 vaccine - LinKinVax
Alternative Names: COVID-19 anti-CD40 CoV2 vaccine; αCD40-RBD vaccine - LinKinVax; αCD40.RBD vaccine - LinKinVaxLatest Information Update: 10 Apr 2023
At a glance
- Originator Vaccine Research Institute
- Developer LinKinVax
- Class COVID-19 vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 19 Feb 2023 Immunogenicity data from a preclinical trial in COVID-2019 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
- 19 Aug 2022 LinKinVax plans a phase I/II trial for COVID-2019 infections (Prevention) in Q4 of 2022 (LinKinVax pipeline, August 2022)
- 24 Mar 2022 Preclinical trials in COVID-2019 infections (Prevention) in France (Parenteral) (LinKinVax pipeline, March 2022)